News Release Details
The three poster presentations highlight assets in Bolt’s preclinical pipeline, including two Boltbody™ immune stimulating antibody conjugate (ISAC) candidates and an agonist antibody. BDC-2034 is a Boltbody ISAC targeting CEA, and the other Boltbody ISAC program targets PD-L1. The company’s proprietary agonist antibody targets Dectin-2 (also known as TAM1). Information about these presentations can be found below and on the 2021 SITC Annual Meeting website.
Title: BDC-2034: Discovery of a CEA-targeting Immune-Stimulating Antibody Conjugate (ISAC) for Solid Tumors
Presenter:
Poster Number: 784
Details:
Title: Dectin-2, a novel target for tumor macrophage reprogramming in cancer immunotherapy
Presenter:
Poster Number: 862
Details:
Title: PD-L1-targeted ISAC combines myeloid cell activation, immune-checkpoint inhibition and ADCP to improve anti-tumor efficacy over anti-PD-L1 antibodies in preclinical models
Presenter:
Poster Number: 782
Details:
About the Boltbody™ Immune-Stimulating Antibody Conjugate (ISAC) Platform
ISACs are a new category of immunotherapy that combines the precision of antibody targeting with the strength of the innate and adaptive immune systems. Boltbody ISACs are comprised of three primary components: a tumor-targeting antibody, a non-cleavable linker, and a proprietary immune stimulant to activate the patient’s innate immune system. By initially targeting a single marker on the surface of a patient’s tumor cells, an ISAC can create a new immune response by activating and recruiting myeloid cells. The activated myeloid cells start a feed-forward loop by releasing cytokines and chemokines, chemical signals that attract other immune cells and lower the activation threshold for an immune response. This reprograms the tumor microenvironment and invokes an adaptive immune response that targets the tumor, with the goal of durable responses for patients with cancer.
About
Investor Relations and Media Contacts:
Vice President, Communications and Investor Relations
650-665-9295
kbergman@boltbio.com
Stern Investor Relations, Inc.
212-362-1200
sarah.mccabe@sternir.com
646-942-5631
maggie.beller@russopartnersllc.com
david.schull@russopartnersllc.com
Source: Bolt Biotherapeutics, Inc.